Heteromultivalent nanoparticle compositions
US-9107963-B2 · Aug 18, 2015 · US
US9833518B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9833518-B2 |
| Application number | US-201514827785-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 17, 2015 |
| Priority date | Apr 13, 2012 |
| Publication date | Dec 5, 2017 |
| Grant date | Dec 5, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.
Opening claim text (preview).
Having described the invention, we claim: 1. A method of delivering a therapeutic and/or imaging agent to activated platelets in a subject, the method comprising administering to the subject a composition, the composition comprising a heteromultivalent nanoparticle or microparticle construct comprising a therapeutic agent and/or imaging agent, the nanoparticle or microparticle construct having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle construct, a first activated platelet targeting moiety comprising a GPIIb-IIIa-binding peptide and a second activated platelet targeting moiety comprising a p-selectin binding peptide, wherein the nanoparticle or microparticle construct remains attached to activated platelets in the subject under a hemodynamic shear environment. 2. The method of claim 1 , the nanoparticle or microparticle construct comprising a liposome. 3. The method of claim 1 , the GPIIb-IIIa-binding peptide comprising a RGD peptide and the p-selectin binding peptide comprising the sequence of SEQ ID NO: 1. 4. The method of claim 3 , the RGD peptide having the sequence of SEQ ID NO: 3. 5. The method of claim 1 , wherein the first and second activated platelet targeting moieties are conjugated to the nanoparticle or microparticle construct surface with PEG linkers. 6. The method of claim 1 , wherein the targeting moieties are spatially or topographically arranged on the nanoparticle or microparticle construct surface such that the GPIIb-IIIa-binding peptide and the p-selectin binding peptide do not spatially mask each other and the nanoparticle or microparticle construct is able to bind to an activated platelet with exposed activated platelet receptors and enhance retention of the nanoparticle or microparticle construct onto activated platelets under hemodynamic flow. 7. The method of claim 6 , wherein the ratio of GPIIb-IIIa-binding peptide to p-selectin binding peptide provided on the nanoparticle or microparticle construct surface is about 80:20 to about 20:80. 8. The method of claim 6 , wherein the GPIIb-IIIa-binding peptide and p-selectin binding peptide provided on the nanoparticle or microparticle construct surface have a total mol % of about 5 to about 20 with respect to total lipid content. 9. The method of claim 1 , wherein the therapeutic agent is a thrombolytic agent and the subject is afflicted with an occlusive vascular disease selected from the group consisting of stroke, myocardial infarction, peripheral arterial diseases and deep vein thrombosis. 10. The method of claim 1 , the nanoparticle or microparticle construct further comprising a plurality of Golden Nanorods (GNRs) conjugated to the surface, the GNRs allowing photothermal destabilization of the nanoparticle or microparticle construct and release of the therapeutic and/or imaging agent in response to near-infrared (NIR) light.
Human Necessities · mapped topic
Methine dyes, e.g. cyanine dyes · CPC title
Urokinase; Tissue plasminogen activator · CPC title
Fluorescein, used in vivo · CPC title
Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.